Hope rises as bowel cancer trial shows no relapses after 33 months

Quick Smiles:

• A bowel cancer trial found no relapses among patients after 33 months of follow-up.
• Participants received pembrolizumab before surgery instead of the usual surgery-then-chemotherapy approach.
• Personalized blood tests helped doctors track tumor response and guide treatment decisions.

A groundbreaking clinical trial has revealed that a short course of immunotherapy before surgery could be a game-changer for bowel cancer patients.

After 33 months of follow-up, researchers found that none of the patients who received the new treatment experienced a return of their disease.

Instead of the traditional approach of surgery followed by chemotherapy, participants received the drug pembrolizumab for nine weeks prior to their operation.

This small shift in the treatment timeline led to major tumor shrinkage and highly durable cancer control for those with high-risk genetic profiles.

Initial results were already promising, with nearly 60 percent of patients showing no signs of disease immediately following the procedure.

Doctors are particularly encouraged because even patients who still had small amounts of cancer remaining after surgery saw no further growth or spread during the observation period.

“Seeing that no patients have experienced a cancer recurrence after almost three years of follow-up is extremely encouraging and strengthens our confidence,” said Dr. Kai-Keen Shiu, the trial’s chief investigator.

Researchers used personalized blood tests to monitor tumor DNA, allowing them to predict which patients were responding best to the immunotherapy.

This technological advance may soon allow doctors to tailor treatments to each individual, potentially reducing the need for aggressive post-operative therapy.

“I feel very lucky that I’ve reached the stage where my main problem is age rather than cancer or any illness,” noted 73-year-old participant Christopher Burston, who has returned to his normal life.

These findings offer incredible hope for the future of cancer care and long-term survival for thousands of families.

Source